High-Dose Intravenous PPI Treatment for Acute Upper GI Bleeding
For patients with bleeding ulcers showing high-risk stigmata (active bleeding or visible vessel) who have undergone successful endoscopic therapy, administer an 80-mg intravenous bolus of PPI followed by continuous infusion at 8 mg/hour for 72 hours. 1
Specific Dosing Regimen
The standard high-dose PPI protocol consists of:
- Initial bolus: 80 mg IV push 1
- Continuous infusion: 8 mg/hour for 72 hours 1
- Post-infusion: Transition to oral PPI twice daily (40 mg) for days 3-14, then once daily thereafter 1
This regimen is supported by moderate-quality evidence demonstrating reduced mortality (OR 0.56, CI 0.34-0.94) and rebleeding (OR 0.43, CI 0.29-0.63) compared to no PPI or H2-receptor antagonists. 1
Alternative Dosing Considerations
While the continuous infusion regimen remains the guideline-recommended approach, intermittent high-dose PPI therapy (twice-daily IV bolus dosing or oral formulation) can be considered as an alternative for patients with high-risk stigmata after endoscopic hemostasis. 2
- Intermittent PPI therapy showed noninferiority to continuous infusion with an absolute risk difference of -2.64% for rebleeding within 7 days (well below the 3% noninferiority margin). 3
- This approach significantly reduces costs and resource utilization without compromising efficacy. 3, 4
Patient-Specific Applications
High-risk stigmata requiring this regimen include: 1
- Forrest Ia: Spurting arterial bleeding
- Forrest Ib: Oozing bleeding
- Forrest IIa: Nonbleeding visible vessel
For adherent clots (Forrest IIb): High-dose PPI therapy is recommended even if endoscopic therapy is not performed. 2, 5
For low-risk lesions (Forrest IIc flat spot or Forrest III clean base): High-dose IV PPI is not indicated; standard oral PPI once daily is sufficient. 5
Timing and Duration
- Pre-endoscopy: Initiate high-dose IV PPI while awaiting endoscopy, but do not delay the procedure. 5
- Post-endoscopy: Continue for full 72 hours if high-risk stigmata confirmed. 1
- After 72 hours: Transition to oral PPI twice daily through day 14 for patients at high risk for rebleeding (Rockall score ≥6), then once daily. 1
Common Pitfalls to Avoid
Overuse in low-risk patients: IV PPIs are frequently continued inappropriately in patients with low-risk or no peptic ulcer disease, with one study showing only 31% of patients received appropriate duration of IV PPI therapy. 6 Discontinue or transition to oral therapy promptly after endoscopy reveals low-risk findings.
Premature discontinuation: The full 72-hour infusion is critical for high-risk lesions, as most rebleeding occurs during this initial period. 7
Inadequate follow-up dosing: After the 72-hour infusion, twice-daily oral PPI (not once-daily) should be used through day 14 in high-risk patients, as this reduces rebleeding (RR 0.37, CI 0.19-0.73). 1
Evidence Quality Considerations
The International Consensus Group provides a strong recommendation with moderate-quality evidence for high-dose IV PPI therapy in this population. 1 However, the evidence comparing high-dose versus non-high-dose regimens shows no significant differences in mortality or rebleeding (low to moderate quality evidence), which explains why alternative intermittent dosing strategies are increasingly accepted. 1, 3